Potential opioid-sparing effect of regular benzodiazepines in dyspnea: Longer duration of studies needed

Journal of Pain and Symptom Management

Volumn 40, Issue 5, 2010, Pages

  Currow, David C ^a   Abernethy, Amy P ^b,c  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; MIDAZOLAM; MORPHINE; OPIATE DERIVATIVE;

CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; HUMAN; LETTER;

ANALGESICS, OPIOID; ANTI-ANXIETY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; HUMANS; MIDAZOLAM; MORPHINE;

EID: 78349304168     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.07.002     Document Type: Letter

References (4)

1. A.H. Navigante, M.A. Castro, and L.C. Cerchietti Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated J Pain Symptom Manage 39 2010 820 830
2. D.C. Currow, J. Wheeler, P. Glare, S. Kaasa, and A.P. Abernethy A framework for generalizability in palliative care J Pain Symptom Manage 37 2009 373 386
3. A.L. Jennings, A.N. Davies, and J.P. Higgins A systematic review of the use of opioids in the management of dyspnoea Thorax 57 2002 939 944
4. A.P. Abernethy, D.C. Currow, and P. Frith Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea BMJ 327 2003 523 528